Roche drops price of breast cancer drug for NICE approval

The National Institute for Health and Care Excellence has changed its position on the routine use of Roche's Perjeta to treat a certain form of breast cancer on the NHS in England and Wales.
Read the full story: PharmaTimes: News RSS